GHAPPcast12 Joulu 2024

FAQ: Describe the IL23/IL17 axis

Thank you to Johnson & Johnson for your support of this FAQ Video Module.

Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from Alaska Digestive and Liver Disease, explores the IL-23/IL-17 axis, a crucial pathway in the pathogenesis of inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, multiple sclerosis, and other immune-mediated disorders.

The IL-23 cytokine plays a pivotal role in promoting Th17 cell differentiation, which in turn produces pro-inflammatory cytokines like IL-17A, IL-17F, tumor necrosis factor (TNF), and IL-6. IL-17, a key driver of chronic inflammation, is overexpressed in patients with autoimmune diseases, contributing to tissue damage, immune dysregulation, and inflammation. These effects are particularly evident in conditions such as Crohn’s disease, ulcerative colitis, and psoriatic arthritis, making the IL-23/IL-17 axis a major target for emerging biologic therapies.

Therapeutic strategies that block IL-23 or its receptor have been FDA-approved for treating psoriasis, psoriatic arthritis, and IBD. By inhibiting this inflammatory pathway, these treatments help reduce disease progression, alleviate symptoms, and improve patient outcomes. Understanding this mechanism is essential for healthcare providers seeking optimized, targeted treatment options for their patients.

For more information on IL-23-targeted therapies and advances in gastroenterology, hepatology, and immune-mediated disease treatment, visit GHAPP.org or download the GHAPP ACE mobile app on Android or IOS. Stay connected with us on LinkedIn, YouTube, X (formerly Twitter), and Instagram for expert insights and updates.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(155)

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min